Julius Magala
ID:
|
Using Data to Catalyze Energy Investments
REFNo: SIR98ES
Main Objective: The overarching goal is to provide improved data on demand for productive energy use across Uganda to inform future actions/investments by the Ugandan Government as well as other stakeholders.
Specific Further Objectives: Our methods will capture data related to agricultural conditions and practices, complemented by spatial analysis. Respondent interviews will focus primarily on cropping and irrigation seasonality. These will be used in combination with numerous field observations (taken without interviews). Finally, the outputs of the CWP effort will emphasize statistical analysis and machine learning in order to make geospatial predictions, identifying areas where a combination of factors establish a higher probability for presence of and success in irrigation.
|
Uganda |
2022-04-12 |
2025-04-12 |
Engineering and Technology |
Non-Clinical Trial |
Non-degree Award |
|
Shelley Jones
ID:
|
COVID-19 as an urgent call for commitment to women's resilience and empowerment: A participatory action research project with vulnerable women in Uganda
REFNo: SS1207ES
The objectives of this project are to work with women in Uganda to develop and pilot a contextually- and culturally-responsive Resiliency and Empowerment Framework (REF) that will foster a community of support that encourages women to self-inventory their skills, knowledge, abilities, and experiences as well as identify and access resources they require to exercise empowerment and work collectively to transform their societies. The REF will be adaptable for women living in diverse contexts throughout the world. As part of REF, participants will create and implement their own, personal multi-stage Resiliency and Empowerment Plans (REPs) that will reflect their own aspirations. These REPs may represent individualistic or collaborative trajectories.
|
Canada |
2022-04-12 |
2025-04-12 |
Social Science and Humanities |
Non-Clinical Trial |
Non-degree Award |
|
Robert Ssekitoleko
ID: UNCST-2019-R001716
|
Impacts of Covid-19 on Provision of Essential Healthcare Services and on Community Networks in Uganda
REFNo: HS2181ES
General Objective
To evaluate the Impact of COVID-19 on provision of essential Healthcare services and on the community networks in Uganda
Specific objectives
1. To determine the Impact of COVID-19 on essential health service delivery in Regional Referral Hospitals in Uganda.
2. To evaluate the actual local activities and collaboration of key stakeholders involved in CES in response to COVID-19 pandemic Uganda.
|
Uganda |
2022-04-07 |
2025-04-07 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Haruna Muwonge
ID: UNCST-2019-R000128
|
A Randomized, Double-Blinded, Placebo-Controlled, Phase III, Clinical Trial of SARS-CoV-2 Vaccine, Inactivated (Vero Cell) in Adults Aged 18 Years and Above
REFNo: HS2185ES
Safety: To evaluate adverse events from the first dose and the booster dose to Day 28 after the whole-course immunization and serious adverse events from the first dose and the booster dose to at least 12 months after the whole-course immunization,Efficacy: To evaluate the efficacy of the SARS-CoV-2 Vaccine, Inactivated (Vero Cell) for symptomatic and laboratory-confirmed (RT-PCR method) COVID-19 cases caused by different SARS-CoV-2 variants,Immunogenicity: To evaluate the immune persistence of the investigational vaccine,Immunogenicity: To demonstrate the consistency of 3 lots of investigational vaccine in terms of GMT 14 days after the whole-course immunization,Immunogenicity: To evaluate the levels of neutralizing antibody and IgG antibody against SARS-CoV-2 14 days after the whole-course and after the booster immunization,Efficacy: To evaluate the efficacy of the SARS?CoV?2 Vaccine, Inactivated (Vero Cell) against symptomatic and laboratory-confirmed (RT?PCR method) severe COVID-19 disease,Efficacy: To evaluate the efficacy of the SARS?CoV?2 Vaccine, Inactivated (Vero Cell) after at least one dose, 2 doses, and after the booster dose of immunization,To evaluate the efficacy, safety and immunogenicity of the SARS?CoV?2 Vaccine, Inactivated (Vero Cell) in adults aged 18 years and above after a 2-dose schedule, and after booster vaccination,
|
Uganda |
2022-04-07 |
2025-04-07 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Aloysius Ssennyonjo Ssennyonjo
ID: UNCST-2021-R013504
|
Evaluating the Impact of the Health Sub-District Strategy on Maternal and Neonatal Health Outcomes in Uganda (2000-2020)
REFNo: HS2169ES
4.To examine lessons learnt, opportunities and recommendations for optimizing the impact of HSD strategy on and health system performance (MNH) in Uganda,3.To explore the mechanisms through which the HSD strategy (and its adaptions) impacted maternal and neonatal health (MNH) outcomes,2.To determine the impact of the HSD strategy on MNH outcomes in Uganda over time and across geographical settings. a)To describe the trends in key health system performance indicators (focusing on MNH) over the same time frame. b) To determine the associations between the HSD strategy and health system performance (MNH outcomes) ,1. To explore how the HSD strategy evolved from 2000 to 2020 and why? a) To describe the critical timelines of the evolution of the HSD strategy. b)To analyze the processes, mechanisms and dynamics that explain the evolutionary process of the HSD strategy,To analyse the impact and underlying mechanisms of the health sub-district strategy on maternal and neonatal health (MNH) outcomes in Uganda from 2000 to 2020. ,
|
Uganda |
2022-04-07 |
2025-04-07 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
.jpg)
|
| View |
|
Sort By: |
|
|
|
| |
|